[Role of anidulafungin in critically ill patients]

Márcio Borges Sá1, José Garnacho Montero

  • 1Unidad de Cuidados Críticos, Servicio de Medicina Intensiva, Hospital Son Llátzer, Palma, Islas Baleares, España. mborges@hsll.es

Insights

Invasive fungal infections, particularly candidemia, are increasing in ICUs, necessitating early diagnosis and new treatments. Anidulafungin offers a new option for immunocompetent patients with invasive candidiasis.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Mycology

Background:

  • Invasive fungal infections, especially invasive candidiasis and candidemia, are prevalent in critically ill patients.
  • There is a rising incidence of non-albicans Candida species causing infections, potentially leading to antifungal resistance.
  • Current diagnostic methods for invasive fungal infections lack reliability, impacting timely and appropriate treatment.

Purpose of the Study:

  • To highlight the increasing challenge of invasive fungal infections in intensive care units (ICUs).
  • To emphasize the need for early and accurate diagnosis to guide therapy.
  • To introduce anidulafungin as a new therapeutic option for invasive candidiasis.

Main Methods:

  • Review of current literature on invasive fungal infections in ICUs.
  • Discussion of diagnostic challenges and emerging strategies like clinical scores.
  • Evaluation of the therapeutic landscape, including new antifungal agents.

Main Results:

  • Invasive candidiasis, including candidemia, is a growing concern in ICUs, with non-albicans species becoming more common.
  • Antifungal resistance is a potential consequence of increased infection rates and empirical treatment.
  • New diagnostic approaches and therapeutic agents are crucial for managing these infections.

Conclusions:

  • Early diagnosis of invasive fungal infections is essential to optimize patient treatment and outcomes in the ICU.
  • Anidulafungin is a valuable addition to the treatment options for invasive candidiasis in immunocompetent critically ill patients.
  • Continued research into diagnostics and therapeutics is vital to combat rising rates of invasive fungal infections.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...